U.S. regulator approves AstraZeneca to resume trials of new crown vaccine

  AstraZeneca suspended more than a month’s trial of the new crown vaccine in the United States and received approval from the US regulatory agency to restart. The new crown vaccine developed by the British drugmaker in cooperation with the University of Oxford was previously suspended due to concerns about the illness of a volunteer.

U.S. regulator approves AstraZeneca to resume trials of new crown vaccine

   according to As Likang and Oxford University stated that the US Food and Drug Administration approved the resumption of the trial on Friday. They stated that the FDA has evaluated the data from the global study and determined that it is safe to start the trial again.

   This decision removed a major obstacle for R&D partners trying to promote the new crown vaccine research sprint. AstraZeneca and the University of Oxford lead the world in the development of new crown vaccines, and other developers include Pfizer and Moderna Inc. . According to Oxford University, the AstraZeneca trial in the United States will test the vaccine on 30,000 volunteers.

   “The cautious attitude of independent regulators to protect the public and ensure vaccine safety before the vaccine is approved should give us peace of mind,” AstraZeneca CEO Pascal Soriot said in a statement. This “enables us to continue to advance the development of this vaccine to help overcome this terrible pandemic.”

   FDA representatives did not immediately respond to a request for comment.

<!– news_keyword_pub,usstock,PFEpadding:8px;} .appendQr_normal{float:left;} .appendQr_normal img{width:74px;} .appendQr_normal_txt{float:left;font-size:20px;line-height :74px;padding-left:20px;color:#333;}

Author:SINA,If you need to reprint,please indicate the source:http://www.todaycamera.com/camera-reviews/u-s-regulator-approves-astrazeneca-to-resume-trials-of-new-crown-vaccine